Loading
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
Latest quote
¥5,260
−¥60.00 · -1.13%
Regular session · JST · Market data may be delayed.
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
Day range
Current ¥5,260
52-week range
Current ¥5,260
Regular session · JST · Market data may be delayed.
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
Day range
Current ¥5,260
52-week range
Current ¥5,260
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 212.33M JPY | 175.21M JPY | 23.1M JPY | 38.28M JPY | 13.91M JPY |
| Cost of goods sold | 166.43M JPY | 83.64M JPY | 83.57M JPY | 95.92M JPY | 96M JPY |
| Gross profit | 45.9M JPY | 91.56M JPY | −60.47M JPY | −57.64M JPY | −82.09M JPY |
| Research and development | — | 334.13M JPY | 209.77M JPY | 648.46M JPY | 112.81M JPY |
| Selling, general, and administrative | 1.13B JPY | 347.69M JPY | 318.24M JPY | 392.79M JPY | 178.37M JPY |
| Operating expenses | 1.13B JPY | 681.82M JPY | 528.02M JPY | 392.79M JPY | 291.11M JPY |
| Interest income | 13.39M JPY | 4.09M JPY | 45K JPY | 11K JPY | — |
| Depreciation and amortization | 84.45M JPY | 76.69M JPY | 70.1M JPY | 78.66M JPY | 92.74M JPY |
| Operating income | −1.08B JPY | −590.26M JPY | −588.49M JPY | −450.44M JPY | −373.2M JPY |
| Net income | −1.02B JPY | −644.34M JPY | −632.18M JPY | −452.08M JPY | −375.34M JPY |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
